Specific therapeutic schemes of omeprazole affect the orientation of Helicobacter pylori

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3511-3514

  Azevedo Vethacke, Marina ^a   Garten, Désirée ^a   Groll, Claudia ^a   Schreiber, Sören ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GERBIL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; NONHUMAN; PRIORITY JOURNAL; SPATIAL ORIENTATION; STOMACH MUCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; GASTRIC MUCOSA; GERBILLINAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; OMEPRAZOLE; PROTON PUMP INHIBITORS;

EID: 67749124291     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00158-09     Document Type: Article

References (23)

1. Bago, P., A. Vcev, M. Tomic, M. Rozankovic, M. Marusic, and J. Bago. 2007. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien. Klin. Wochenschr. 119:372-378.
2. Bazzoli, F., R. M. Zagari, P. Pozzato, S. Fossi, L. Ricciardiello, G. Nicolini, L. De Luca, D. Berretti, G. Alampi, C. Di Pietro, P. Morelli, and E. Roda. 2002. Low-dose lansoprazole and clarithromycin plus metronidazole vs. fulldose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 16:153-158.
3. Bren, A., and M. Eisenbach. 2000. How signals are heard during bacterial chemotaxis: protein-protein interactions in sensory signal propagation. J. Bacteriol. 182:6865-6873.
4. Brenner, H., V. Arndt, C. Stegmaier, H. Ziegler, and D. Rothenbacher. 2004. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am. J. Epidemiol. 159:252-258.
5. Choi, H. S., D. I. Park, S. J. Hwang, J. S. Park, H. J. Kim, Y. K. Cho, C. I. Sohn, W. K. Jeon, and B. I. Kim. 2007. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 12:638-642.
6. Croxen, M. A., G. Sisson, R. Melano, and P. S. Hoffman. 2006. The Helicobacter pylori chemotaxis receptor TlpB (HP0103) is required for pH taxis and for colonization of the gastric mucosa. J. Bacteriol. 188:2656-2665.
7. Ekström, A. M., M. Held, L. E. Hansson, L. Engstrand, and O. Nyren. 2001. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121:784-791.
8. Graham, D. Y., S. Abudayyeh, H. M. El-Zimaity, J. Hoffman, R. Reddy, and A. R. Opekun. 2006. Sequential therapy using high-dose esomeprazoleamoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 24:845-850.
9. Graham, D. Y., H. Lu, and Y. Yamaoka. 2008. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 68:725-736.
10. Guslandi, M., M. Franceschi, L. Fanti, A. Pellegrini, and A. Tittobello. 1992. Omeprazole-induced changes in gastric mucus secretion. Methods Find. Exp. Clin. Pharmacol. 14:219-223.
11. Gustavson, L. E., J. F. Kaiser, A. L. Edmonds, C. S. Locke, M. L. DeBartolo, and D. W. Schneck. 1995. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. 39:2078-2083.
12. Hosking, S. W., T. K. Ling, M. Y. Yung, A. Cheng, S. C. Chung, J. W. Leung, and A. K. Li. 1992. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ 305:502-504.
13. Jafri, N. S., C. A. Hornung, and C. W. Howden. 2008. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 148:923-931.
14. Kuipers, E. J., J. C. Thijs, and H. P. Festen. 1995. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment. Pharmacol. Ther. 9(Suppl. 2):59-69.
15. Matysiak-Budnik, T., and F. Megraud. 1997. Epidemiology of Helicobacter pylori infection with special reference to professional risk. J. Physiol. Pharmacol. 48(Suppl. 4):3-17.
16. Nista, E. C., M. Candelli, M. A. Zocco, I. A. Cazzato, F. Cremonini, V. Ojetti, M. Santoro, R. Finizio, G. Pignataro, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. 2005. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 21:1241-1247.
17. Schreiber, S., R. Bucker, C. Groll, M. Azevedo-Vethacke, P. Scheid, S. Gatermann, C. Josenhans, and S. Suerbaum. 2006. Gastric antibacterial efficiency is different for pepsin A and C. Arch. Microbiol. 184:335-340.
18. Schreiber, S., R. Bücker, C. Groll, M. Baptista, D. Garten, P. Scheid, S. Friedrich, C. Josenhans, and S. Suerbaum. 2005. Rapid loss of motility of Helicobacter pylori in the gastric lumen in vivo. Infect. Immun. 73:1584-1589.
19. Schreiber, S., M. Konradt, C. Groll, P. Scheid, G. Hanauer, H. O. Werling, C. Josenhans, and S. Suerbaum. 2004. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc. Natl. Acad. Sci. USA 101:5024-5029.
20. Schreiber, S., and P. Scheid. 1997. Gastric mucus of the guinea pig: proton carrier and diffusion barrier. Am. J. Physiol. 272:G63-G70.
21. Schreiber, S., M. Stüben, C. Josenhans, P. Scheid, and S. Suerbaum. 1999. In vivo distribution of Helicobacter felis in the gastric mucus of the mouse: experimental method and results. Infect. Immun. 67:5151-5156.
22. Suerbaum, S., and P. Michetti. 2002. Helicobacter pylori infection. N. Engl. J. Med. 347:1175-1186.
23. Vaira, D., A. Zullo, N. Vakil, L. Gatta, C. Ricci, F. Perna, C. Hassan, V. Bernabucci, A. Tampieri, and S. Morini. 2007. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. 146:556-563.